Sign in

    Nazibur Rahman • Maxim Group

    Nazibur Rahman is an Equity Analyst at Maxim Group, specializing in coverage of small-cap healthcare and biotechnology companies. He has provided analyst ratings for firms such as NexGel Inc. and Neurosense Therapeutics Ltd., with a success rate around 29% and an average return of approximately -17.8% on his stock recommendations according to public performance data. Rahman has been actively publishing equity research for Maxim Group into at least 2025, focusing his analysis on innovative medical technology and specialty pharmaceutical companies, though prior career information is not widely published. His research reports and analyst credentials indicate familiarity with FINRA-compliant practices and a professional regulatory standing typical for equities research roles at major brokerages.

    Nazibur Rahman's questions to Aytu Biopharma Inc (AYTU) leadership

    Nazibur Rahman's questions to Aytu Biopharma Inc (AYTU) leadership • Q3 2025

    Question

    Nazibur Rahman of Maxim Group asked about potential one-time revenue effects, the sustainability of ADHD franchise growth, the recovery potential for the Pediatrics business, gating factors for business development, and the potential impact of tariffs or other legislation.

    Answer

    Executive Joshua Disbrow confirmed there were no one-time stocking effects, attributing growth to organic performance. He expressed confidence in maintaining and growing ADHD revenue levels. For the Pediatrics business, he projected growth from current levels but likely not back to its peak $25M annualized run rate. Disbrow identified finding the 'right fit' for an acquisition—a commercial-stage CNS asset—as the primary gating factor for business development, noting valuations are somewhat high. He also stated that tariffs would have a 'de minimis' impact due to U.S.-based manufacturing and that the company is monitoring potential regulatory changes around fluoride.

    Ask Fintool Equity Research AI

    Nazibur Rahman's questions to Aytu Biopharma Inc (AYTU) leadership • Q4 2024

    Question

    Nazibur Rahman of Maxim Group asked a series of questions regarding Aytu's performance and strategy, including the drivers behind Q4 ADHD sales weakness, the go-forward plan for managed care contracting, the potential impact from increased generic Vyvanse supply, the strategic outlook for the recovering pediatric business, and the company's long-term vision for growth beyond its current portfolio.

    Answer

    CEO Joshua Disbrow addressed the questions, explaining that Q4 ADHD revenue was impacted by the normalization of a prior-quarter payer issue and that underlying prescription demand remains at an all-time high. He stated Aytu remains flexible on payer contracts, leveraging its RxConnect platform to ensure patient access. Disbrow sees minimal impact from Vyvanse quota changes, as Aytu's growth comes from gaining small market share. He affirmed the pediatric business is a core asset not for sale, with recovery efforts expected to drive meaningful EBITDA contribution. Long-term, the strategy involves tucking in synergistic products via RxConnect and disciplined M&A once free cash flow is achieved.

    Ask Fintool Equity Research AI

    Nazibur Rahman's questions to Nexgel Inc (NXGL) leadership

    Nazibur Rahman's questions to Nexgel Inc (NXGL) leadership • Q1 2025

    Question

    Nazibur Rahman of Maxim Group inquired about the impact of the AbbVie launch delay on 2025 revenue guidance, the market opportunity for the new product with STADA, and the growth trajectory and marketing strategy for the Histosol product, particularly regarding TikTok. He also asked about the operational and financial implications of potentially moving manufacturing to Texas due to tariffs and sought details on further margin optimization for the company's consumer brands.

    Answer

    Adam Levy, an executive, clarified that the AbbVie delay has a minimal impact on the $13 million revenue guidance as little was initially factored in. He explained the new STADA product is another digestive enzyme in a line extension strategy. Levy noted that Histosol sales continue to grow monthly, but a TikTok marketing push is on hold pending clarity on the platform's future. Regarding tariffs, moving manufacturing to Texas is a contingency plan ('Plan C') if rates become untenable, but the current 35% rate is manageable. He also confirmed that brand margins are improving through more efficient ad spend, with Q1 being the most profitable quarter for the brand despite not having the highest sales.

    Ask Fintool Equity Research AI

    Nazibur Rahman's questions to Nexgel Inc (NXGL) leadership • Q4 2024

    Question

    Nazibur Rahman asked about the expected cadence to achieve positive adjusted EBITDA, the size and breadth of the new customer pipeline, the market opportunity and promotional strategy for the innovative optics partnership, and for an update on the AbbVie Resonic device launch.

    Answer

    Executive Adam Levy stated that NEXGEL expects to reach positive adjusted EBITDA 'pretty quickly,' with improvements in Q1 and a significant ramp-up in Q2 driven by new customers. He described the new customer pipeline as having 4-5 large, long-cycle opportunities at any given time, spanning simple devices to more complex diagnostics. For the innovative optics product, Levy noted they are partnering with a firm that has existing industry relationships and expect to begin selling mid-year 2025. Regarding AbbVie, he confirmed they are on schedule to ship initial product orders in Q2 2025.

    Ask Fintool Equity Research AI

    Nazibur Rahman's questions to Nexgel Inc (NXGL) leadership • Q3 2024

    Question

    Nazibur Rahman asked about NEXGEL's strategic initiatives after achieving positive cash flow, the regulatory steps and commercial timeline for the laser hair removal hydrogel, the expected revenue impact from the holiday season, and the progress on expanding distribution into Europe and U.S. retail.

    Answer

    CEO Adam Levy explained that reaching positive cash flow enables a strategic shift to 'offense,' including potential acquisitions and expansion. He clarified the laser hair removal study is for commercial marketing claims, not regulatory approval, with revenues anticipated in the first half of 2025. Levy expects a significant holiday sales increase for the Silly George brand, though the exact scale is uncertain. He also mentioned European distribution deals are expected in H1 2025, and discussions with major U.S. retailers for Silverseal are ongoing for a potential 2025 launch.

    Ask Fintool Equity Research AI

    Nazibur Rahman's questions to Assertio Holdings Inc (ASRT) leadership

    Nazibur Rahman's questions to Assertio Holdings Inc (ASRT) leadership • Q1 2025

    Question

    Nazibur Rahman of Maxim Group inquired about the progress of expanding Rolvedon into the hospital setting and sought rationale for maintaining the full-year adjusted EBITDA guidance despite Q1 results.

    Answer

    Executive Brendan O’Grady explained that successful hospital expansion for Rolvedon is contingent on growing commercial payer coverage, which the company is actively pursuing with plans for expansion in the second half of the year. Regarding guidance, O'Grady stated that it is too early to make adjustments and the company is still tracking within its established ranges for both net sales and EBITDA, with a potential update in August.

    Ask Fintool Equity Research AI

    Nazibur Rahman's questions to Assertio Holdings Inc (ASRT) leadership • Q4 2024

    Question

    Nazibur Rahman asked about the commercial impact of the Rolvedon same-day dosing data, questioning if there has been an uptick in its use and the timeline for getting the data included in NCCN guidelines to drive future adoption.

    Answer

    CEO Brendan O’Grady stated that there has not yet been a significant commercial impact from the same-day dosing data, which was first presented in December. He outlined the strategy for 2025, which involves publishing the data in a peer-reviewed journal and then approaching the NCCN for guideline inclusion in the second half of the year, though inclusion is not guaranteed. He anticipates a gradual increase in usage as physician awareness grows.

    Ask Fintool Equity Research AI

    Nazibur Rahman's questions to Assertio Holdings Inc (ASRT) leadership • Q3 2024

    Question

    Nazibur Rahman from Maxim Group asked two questions regarding ROLVEDON: first, at what point the pricing decline might stabilize, and second, the potential timeline and logistics for incorporating the upcoming same-day dosing data into NCCN guidelines.

    Answer

    CFO Ajay Patel addressed pricing, stating that the GCSF market remains highly competitive, and he anticipates the trend of pricing declines will continue as market share stabilizes. An executive, Brendan O’Grady, handled the NCCN question, explaining that after the data is presented in December, there is roughly a six-month window to work with NCCN, suggesting a potential guideline update between the middle and end of the following year.

    Ask Fintool Equity Research AI

    Nazibur Rahman's questions to Talphera Inc (TLPH) leadership

    Nazibur Rahman's questions to Talphera Inc (TLPH) leadership • Q4 2024

    Question

    Nazibur Rahman from Maxim Group questioned what gives management confidence in completing the Phase III NEPHRO trial by year-end, considering the time required to activate new clinical sites.

    Answer

    CEO Vince Angotti expressed confidence due to the advanced stage of new site activation and the favorable math of having 13 sites to enroll the remaining patients. Chief Medical Officer Dr. Shakil Aslam added that his confidence stems from the high level of engagement from new nephrologist PIs, who are highly motivated to get Niyad approved as it solves a significant, daily clinical challenge for them and their patients.

    Ask Fintool Equity Research AI